Atlas Trials

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Clinical trial NCT05856084 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05856084
Sponsor
MAXVAX Biotechnology Limited Liability Company
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Herpes Zoster
Start date
2023-05-07
Primary completion
2024-12-28
Enrollment
924

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.